Therapeutic potential of GLP‐1 agonists for hidradenitis suppurativa
International Journal of Dermatology · 2023
DOI: 10.1111/ijd.16892 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Dermatology, 2023. Verfasst von Tanya Henry und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Illinois, College of Medicine, Chicago, IL, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Hidradenitis Suppurativa, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Illinois, College of Medicine, Chicago, IL, USA.
- Department of Dermatology, University of Illinois, Chicago, IL, USA.
- Lovell Federal Health Care Center, North Chicago, IL, USA.
- Department of Bariatric Surgery, University of Illinois, Chicago, IL, USA.
- Department of Dermatology, Northwestern Medicine, Chicago, Illinois, USA.
Zitieren
APA
Henry, T., Cahn, B., Haber, R., Landers, J. T., Berger-Fleishman, R., Alam, M., & Hoyer, S. (2023). Therapeutic potential of GLP‐1 agonists for hidradenitis suppurativa. International Journal of Dermatology. https://doi.org/10.1111/ijd.16892
Vancouver
Henry T, Cahn B, Haber R, Landers JT, Berger-Fleishman R, Alam M, et al. Therapeutic potential of GLP‐1 agonists for hidradenitis suppurativa. International Journal of Dermatology. 2023. doi:10.1111/ijd.16892
BibTeX
@article{Henry2023,
author = {Henry, Tanya and Cahn, Brian and Haber, Roger and Landers, John T and Berger-Fleishman, Reed and Alam, Murad and Hoyer, Sheryl},
title = {Therapeutic potential of GLP‐1 agonists for hidradenitis suppurativa},
journal = {International Journal of Dermatology},
year = {2023},
doi = {10.1111/ijd.16892}
}
EUVIMED